Solid organ transplant complications
Solid organ transplant complications arise from the immunosuppression that prevents graft rejection, producing a predictable, time-dependent pattern of rejection, opportunistic infection, and malignancy. Diagnosis rests on allograft biopsy and pathogen-specific testing, and first-line treatment pairs targeted therapy of the complication with a deliberate adjustment, not blanket discontinuation, of the immunosuppressive regimen.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
Solid organ transplant complications are the predictable result of the immunosuppression that keeps a kidney, liver, heart, or lung graft from being rejected.
- Epidemiology
Kidney is the dominant graft type, so most complication data come from kidney recipients, though the same principles apply across organs.
- Risk factors
HLA mismatch and prior sensitization: fewer shared HLA alleles raises rejection risk, and prior transfusion, pregnancy, or transplantation can generate preformed anti-HLA antibodies that raise antibody-mediated rejection risk.
- Pathophysiology
Rejection is classified by timing and mechanism.
- Clinical features
Hyperacute rejection: graft ischemia and thrombosis within minutes of vascular anastomosis, the organ mottled and failing to perfuse on the table.
- Differential diagnosis
T-cell-mediated acute rejection: interstitial lymphocytic infiltrate with tubulitis on biopsy, but antibody-mediated rejection shows microvascular inflammation and a positive donor-specific antibody titer.
- Diagnosis
What establishes the diagnosis: allograft biopsy is the gold standard for rejection, distinguishing T-cell-mediated from antibody-mediated disease; for infection, quantitative nucleic acid…
- Management
First, adjust immunosuppression: for BK nephropathy and PTLD, stepwise reduction is the primary intervention, balanced against precipitating rejection.
- Complications
Graft failure: the end point of unresolved rejection, requiring dialysis or organ-specific supportive care and evaluation for retransplantation.
- Prognosis
Modern immunosuppression has improved outcomes: graft failure from rejection has decreased as regimens and pretransplant HLA and antibody screening have improved.
- Prevention
CMV prophylaxis: valganciclovir 900 mg PO once daily for 3 to 6 months (100 to 200 days) in at-risk recipients, particularly D+/R- pairings, or equivalent pre-emptive therapy triggered by rising viral load.
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Cytomegalovirus (CMV) infection
Cytomegalovirus is a ubiquitous herpesvirus that is usually asymptomatic or causes a heterophile-negative mononucleosis-like illness in healthy hosts, but reactivates to cause retinitis, colitis, pneumonitis, or encephalitis in transplant recipients and patients with AIDS; treatment is systemic ganciclovir or valganciclovir, with foscarnet and cidofovir reserved for resistance or intolerance.
- Pneumocystis jirovecii pneumonia
Pneumocystis jirovecii pneumonia is a subacute, often hypoxic pneumonia in patients with CD4 counts below 200/mcL or comparable immunosuppression, diagnosed by organism visualization on induced sputum or bronchoalveolar lavage and treated with 21 days of high-dose trimethoprim-sulfamethoxazole plus adjunctive steroids when hypoxic.
- Kaposi sarcoma
Kaposi sarcoma is a human herpesvirus 8-associated vascular malignancy that presents as violaceous macules, papules, plaques, or tumors of the skin, mouth, gastrointestinal tract, or lungs, most often in HIV-associated, transplant-related, or classic elderly disease. Diagnosis is confirmed by biopsy. Every patient with HIV-associated Kaposi sarcoma starts or optimizes antiretroviral therapy, with liposomal doxorubicin 20 mg/m2 intravenously every 21 days added for extensive or visceral disease.
- Graft-versus-host disease
Graft-versus-host disease is a complication of allogeneic hematopoietic stem cell transplantation in which donor T cells attack recipient tissues, classically the skin, liver, and gut in the acute form and multi-organ fibrosis in the chronic form. Diagnosis is clinical, supported by biopsy, and management is prophylaxis with a calcineurin inhibitor plus methotrexate and treatment with corticosteroids, escalating to agents such as ruxolitinib for steroid-refractory disease.
- Acute kidney injury
Acute kidney injury is a sudden rise in serum creatinine or fall in urine output from prerenal, intrinsic, or postrenal causes, defined and staged by KDIGO criteria. Management targets the underlying cause, corrects volume and electrolyte derangements, and escalates to renal replacement therapy for refractory hyperkalemia, acidosis, volume overload, or uremia.
- Aspergillosis
Invasive aspergillosis is an angioinvasive mold infection of neutropenic and immunosuppressed hosts that begins in the respiratory tract and disseminates hematogenously, diagnosed with CT, galactomannan, and biopsy, and treated first-line with voriconazole.
- Non-Hodgkin lymphoma
Non-Hodgkin lymphoma is a heterogeneous group of B-cell (about 85%) and T-cell lymphoid malignancies that spread noncontiguously and often involve extranodal sites, ranging from indolent follicular lymphoma to aggressive diffuse large B-cell lymphoma to highly aggressive Burkitt lymphoma. Diagnosis requires excisional or core biopsy with flow cytometry and cytogenetics, Ann Arbor staging with PET-CT, and treatment is subtype-specific, from observation to R-CHOP to intensive Burkitt regimens with aggressive tumor lysis and CNS prophylaxis.
- Urinary tract infections (UTIs), including pyelonephritis
Urinary tract infection spans uncomplicated cystitis, presenting with dysuria, frequency, and suprapubic pain, through pyelonephritis, presenting with fever, flank pain, and costovertebral angle tenderness, most often from ascending Escherichia coli. Uncomplicated cystitis is treated empirically without culture using nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin, while pyelonephritis requires a pre-treatment urine culture and empiric fluoroquinolone or cephalosporin therapy, escalated to hospitalization and broader parenteral coverage for hemodynamic instability, obstruction, or failure to improve.